Is There a Role for Biweekly Romiplostim in the Management of Chronic Immune Thrombocytopenia (ITP)? A Report of Three Cases

Case Reports in Hematology
doi 10.1155/2018/6037494
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Hindawi Limited

Related search

Highly Fluctuating Thrombocytopenia Developing in a Patient With Immune Thrombocytopenia (ITP) While Administering Romiplostim

Internal Medicine
Internal MedicineMedicine
2012English

Self-Administration of Romiplostim in Patients With Chronic Immune Thrombocytopenia

Community Oncology
2013English

Romiplostim for the Management of Perioperative Thrombocytopenia

British Journal of Haematology
Hematology
2018English

The Efficacy and Safety of Romiplostim in Adult Patients With Chronic Immune Thrombocytopenia

Therapeutic Advances in Hematology
Hematology
2012English

A Single Center Experience With Romiplostim for the Management of Chemotherapy-Induced Thrombocytopenia

American Journal of Hematology
Hematology
2018English

Relative Potency of the Thrombopoietin Receptor Agonists Eltrombopag, Avatrombopag and Romiplostim in a Patient With Chronic Immune Thrombocytopenia

British Journal of Haematology
Hematology
2018English

Determining the Cost of a Bleeding-Related Episode in Primary Adult Chronic Immune Thrombocytopenia (ITP) in the United States

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Evolution of Platelet Function in Adult Patients With Chronic Immune Thrombocytopenia on Romiplostim Treatment

British Journal of Haematology
Hematology
2019English

An Update on the Immunopathology of Immune Thrombocytopenia (ITP)

Pathology
Forensic MedicinePathology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy